Vaccine Global Implementation

An interactive Wall Display and Data Visualization

This project is aimed to engage public interest in vaccination and the global effort to combat infectious diseases. It is designed as an interactive wall display at the size of 25" by 40".  People can explore how vaccine is developed, how long it takes to innovate and make a new vaccine, whether vaccine was efficient in controlling the disease, what countries have adopted the vaccines of investigation into their national vaccination schedule. 

Interactive Mockup Demo

The Content

The interactive dashboard welcomes the visitors, and the question mark button direct them to see the four components that can be found in this display:

  • Development process

  • Development timeline

  • Disease incidence and vaccine coverage

  •  Vaccine schedule implementation

A Collaborative Multi-staged Process

It is a complex process to design and develop a new vaccine. From the initial discovery of the infectious agents to finally the production of vaccine in public market, there are multiple stages and they require collaboration from both private and public sectors. 

 

The development stages are clickable for people to get more information. Check out an infographic poster of the artwork here.

Racing against Time

The combat with infectious diseases is like a race against time. It could take decades to develop an effective and safe vaccine in the past. As science and technology advance, this timeline has been greatly reduced in recent 60 years. Many infectious diseases that used to be deadly can now be prevented by vaccines.

Reducing the Disease Incidence

The license of a vaccine is not the endpoint. It takes time for countries to adopt a new vaccine. It also takes time for the vaccination to show effects.  When there is a large vaccine coverage globally, the disease incidence drops greatly, and this is the case for many infectious diseases such as measles, rubella, and polio etc. 

Starting the Prevention Early

Many countries have established national vaccine schedules for their citizens to get protection from various infectious diseases from an early age. This part illustrates seven most widely adopted vaccines and where they are implemented. 

Legends.png
Legends.png
Legends.png
Legends.png
Legends.png
Legends.png
Legends.png
IPV-01.png
BCG countries-01.png
PCV-01.png
OPV-01.png
HPV-01.png
MMR-01.png
YFV-01.png

Faculty advisor

Dr. Jodie Jenkinson

Medium/Software

Adobe Illustrator, Adobe XD

Final presentation format

Interactive wall display: 40 x 25 inches

Primary audience

Educated lay audience

Data Source

WHO. Retrieved online in 2020

Reference

  1. Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R. Barr, E. (2006). GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side. Clinical Pharmacology & Therapeutics, 81(2), 259-264. doi:10.1038/sj.clpt.6100055

  2. Cunningham, A. L., Garcon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52), 6655-6664. https://doi.org/10.1016/j.vaccine.2016.10.016

  3. Callaway, E., (2020, April 28). The race for coronavirus vaccines: a graphical guide. Nature News Feature. https://www.nature.com/articles/d41586-020-01221-y

  4. Siddiqui, M. A. A., & Perry, C. M. (2006). Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, 66(9), 1263-1271. https://doi.org/10.2165/00003495-200666090-00008

  5. Villa, L. L., Costa, R. L., & Petta, C. A. et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271-278. https://doi.org/10.1016/S1470-2045(05)70101-7

  6. Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11, S16-S19. https://doi.org/10.1038/nm1218

  7. Block, S. L., Brown, D. R., & Chatterjee, A. et al. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95-101. doi: 10.1097/INF.0b013e3181b77906.

  8. Serdobova, I. & Kieny, MP. (2011). Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 96, 1554-1559. https://doi.org/10.2105/AJPH.2005.074583